Tag: Immunochemotherapy breakthrough

Home / Immunochemotherapy breakthrough

Categories

Pembrolizumab with chemotherapy is approved by the USFDA for HER2-negative gastric or gastroesophageal junction adenocarcinoma

The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with fluoropyrimidine- and platinum-containing chemotherapy on November 16, 2023. This approval is for the ini...
immunochemotherapy-breakthrough

We Are Online! Chat With Us!
Scan the code